JP5155857B2 - 移植腎の拒絶の早期認識のためのポリペプチドマーカー - Google Patents
移植腎の拒絶の早期認識のためのポリペプチドマーカー Download PDFInfo
- Publication number
- JP5155857B2 JP5155857B2 JP2008518827A JP2008518827A JP5155857B2 JP 5155857 B2 JP5155857 B2 JP 5155857B2 JP 2008518827 A JP2008518827 A JP 2008518827A JP 2008518827 A JP2008518827 A JP 2008518827A JP 5155857 B2 JP5155857 B2 JP 5155857B2
- Authority
- JP
- Japan
- Prior art keywords
- markers
- polypeptide
- sample
- rejection
- measured
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 73
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 63
- 229920001184 polypeptide Polymers 0.000 title claims description 62
- 210000003734 kidney Anatomy 0.000 title claims description 21
- 238000000034 method Methods 0.000 claims description 41
- 239000003550 marker Substances 0.000 claims description 27
- 238000005251 capillar electrophoresis Methods 0.000 claims description 25
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 210000002700 urine Anatomy 0.000 claims description 11
- 238000004949 mass spectrometry Methods 0.000 claims description 10
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 8
- 235000019253 formic acid Nutrition 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 238000013508 migration Methods 0.000 claims description 7
- 230000005012 migration Effects 0.000 claims description 7
- 239000011521 glass Substances 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 238000001616 ion spectroscopy Methods 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 239000000523 sample Substances 0.000 description 52
- 238000000738 capillary electrophoresis-mass spectrometry Methods 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000001736 capillary Anatomy 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000000132 electrospray ionisation Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 101710198774 Envelope protein US9 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 238000001731 electrophoresis-mass spectrometry Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000001425 electrospray ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000004305 normal phase HPLC Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000000756 surface-enhanced laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
Description
表1:移植腎の拒絶を認識するためのポリペプチドマーカーおよびその分子量(Da)および泳動時間(CE時間(分)):
表2:移植腎の拒絶の認識のためのポリペプチドマーカー(頻度マーカー)、その分子量および泳動時間、およびNTx後の拒絶有りの患者の群および対照群すなわちNTx後の拒絶無しの患者における係数としてその存在および非存在(1=100%,0=0%;実施例に記載の通り試料処理および測定)。
表3:振幅マーカー(ppm正規化)
表4:振幅マーカー(正規化機能を有する)
れた数のポリペプチドマーカーを使用するので十分である。ESI−TOF MS装置にオンラインで連結されたCEを含むCE−MS法がさらに好ましい。
NTx後の拒絶を認識するためのポリペプチドマーカーを検出するために、尿を用いた。尿はNTx後の拒絶を有する患者から、およびNTx後の拒絶無しの患者(対照群)から採取された。
CE−MS測定は、ベックマン・コールター社のキャピラリー電気泳動システム(P/ACE MDQシステム;Beckman Coulter Inc.,米国フラートン(Fullerton))およびブルカーESI−TOF質量分析計(micro−TOFMS、ブルカー・ダルトニクス社(Bruker Daltonik)、ドイツ、ブレーメン)を用いて実施された。
CE測定を点検および較正するために、選択された条件下での記載のCE泳動時間によって特徴づけられる下記のタンパク質またはポリペプチドが用いられた:
タンパク質/ポリペプチド CE泳動時間
アプロチニン(シグマ社(SIGMA)、ドイツ・タウフキルヒェン(Taufkirchen)、品番A1153) 9.2分
リボヌクレアーゼ(シグマ社、ドイツ・タウフキルヒェン、品番R4875)10.9分
リゾチーム(シグマ社、ドイツ・タウフキルヒェン、品番L7651) 8.9分
"REV"、配列:REVQSKIGYGRQIIS 15.6分
"ELM"、配列:ELMTGELPYSHINNRDQIIFMVGR 23.4分
"KINCON"、配列:TGSLPYSHIGSRDQIIFMVGR 20.0分
"GIVLY"配列:GIVLYELMTGELPYSHIN 36.8分
Claims (8)
- 試料においてマーカー1ないし242(頻度マーカー)から選択される少なくとも一つのポリペプチドマーカーの存在または非存在を測定する段階;または
試料においてマーカー243ないし767(振幅マーカー)から選択される少なくとも一つのポリペプチドマーカーの振幅を測定する段階
を含む、腎臓移植(NTx)後の拒絶を認識するためのポリペプチドマーカーを検出する方法であって、
上記マーカー1ないし767は、質量および泳動時間(CE時間)について下記の表に記載の値によって特徴づけられるポリペプチドマーカーであり、
上記CE時間の値は、長さ90cm及び内径(ID)50μmのガラスキャピラリーを用い、かつ移動溶媒として20%アセトニトリル及び0.25Mギ酸の水溶液を用いたキャピラリー電気泳動によって付加電圧25kVにおいて測定される値であり、
上記段階において、少なくとも3種類のポリペプチドマーカーが測定され、及び
上記試料は尿試料である、上記方法。
- 上記段階において、請求項1で定義される少なくとも5種類または少なくとも10種類またはすべてのポリペプチドマーカーが測定される、請求項1から3のいずれかに記載の方法。
- キャピラリー電気泳動、HPLC、気相イオンスペクトル法および/または質量分析が、一または複数のポリペプチドマーカーの存在または非存在を検出するのに用いられる、請求項1から4のいずれかに記載の方法。
- キャピラリー電気泳動が、ポリペプチドマーカーの質量が測定される前に実施される、請求項1から5のいずれかに記載の方法。
- 質量分析が、一または複数のポリペプチドマーカーの存在または非存在を検出するのに用いられる、請求項1から6のいずれかに記載の方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05105822 | 2005-06-29 | ||
EP05105822.0 | 2005-06-29 | ||
DE102005058514.0 | 2005-12-08 | ||
DE102005058514 | 2005-12-08 | ||
EP05112767 | 2005-12-22 | ||
EP05112767.8 | 2005-12-22 | ||
PCT/EP2006/063635 WO2007000466A1 (de) | 2005-06-29 | 2006-06-28 | Polypeptidmarker zur frühzeitigen erkennung der rejektion von transplantierten nieren |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008545130A JP2008545130A (ja) | 2008-12-11 |
JP5155857B2 true JP5155857B2 (ja) | 2013-03-06 |
Family
ID=36933512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008518827A Expired - Fee Related JP5155857B2 (ja) | 2005-06-29 | 2006-06-28 | 移植腎の拒絶の早期認識のためのポリペプチドマーカー |
Country Status (4)
Country | Link |
---|---|
US (2) | US20100200401A1 (ja) |
EP (1) | EP1896856A1 (ja) |
JP (1) | JP5155857B2 (ja) |
WO (1) | WO2007000466A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2534432T3 (es) | 2008-07-31 | 2015-04-22 | Queen Mary And Westfield College, University Of London | Biomarcadores de riñón sano |
EP2462447A4 (en) | 2009-08-07 | 2013-01-30 | Rules Based Medicine Inc | METHODS AND DEVICES FOR DETECTING RENAL INJURY |
WO2018117011A1 (ja) | 2016-12-19 | 2018-06-28 | 国立大学法人大阪大学 | インビトロでのIgM型メモリーB細胞分化培養系を用いた臓器移植後抗体関連型拒絶反応の早期診断法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5340721A (en) * | 1991-07-26 | 1994-08-23 | Board Of Regents, The University Of Texas System | Assay for free secretory component and methods for monitoring organ rejection |
DE10021737C2 (de) * | 2000-05-04 | 2002-10-17 | Hermann Haller | Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird |
DE10341193A1 (de) * | 2003-09-06 | 2005-03-31 | Mosaiques Diagnostics And Therapeutics Ag | Vorrichtung und Verfahren zur quantitativen Auswertung der in einer Körperflüssigkeitsprobe enthaltenden Polypeptide sowie Marker zur Erkennung von pathologischen Zuständen |
-
2006
- 2006-06-28 US US11/922,550 patent/US20100200401A1/en not_active Abandoned
- 2006-06-28 EP EP06763931A patent/EP1896856A1/de not_active Withdrawn
- 2006-06-28 WO PCT/EP2006/063635 patent/WO2007000466A1/de active Application Filing
- 2006-06-28 JP JP2008518827A patent/JP5155857B2/ja not_active Expired - Fee Related
-
2014
- 2014-11-26 US US14/554,368 patent/US20150126405A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20150126405A1 (en) | 2015-05-07 |
JP2008545130A (ja) | 2008-12-11 |
EP1896856A1 (de) | 2008-03-12 |
US20100200401A1 (en) | 2010-08-12 |
WO2007000466A1 (de) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20150024970A1 (en) | Kidney cell carcinoma | |
US20110036717A1 (en) | Method and marker for diagnosis of tubular kidney damage and illness | |
US20150133343A1 (en) | Polypeptide markers for the diagnosis of prostate cancer | |
AU2006283851B2 (en) | Polypeptide marker for the diagnosis of bladder cancer | |
US20140073057A1 (en) | Process and markers for the diagnosis of kidney diseases | |
US20100062537A1 (en) | Polypeptide Markers for the Diagnosis and Evaluation of Pelvi-Ureteric Junction Obstruction (PUJO) | |
US20150018246A1 (en) | Polypeptide marker for diagnosing and assessing vascular diseases | |
US20120118737A1 (en) | Method And Markers For Diagnosing Acute Renal Failure | |
US20150346150A1 (en) | Autosomal-dominant polycystic kidney disease (adpkd) | |
US20100248378A1 (en) | Method and marker for diagnosing diabetes mellitus | |
US20100227411A1 (en) | Polypeptide markers for the diagnosis of prostate cancer | |
JP5155857B2 (ja) | 移植腎の拒絶の早期認識のためのポリペプチドマーカー | |
JP5147684B2 (ja) | アルツハイマー病の診断のためのポリペプチドマーカー | |
RU2405159C2 (ru) | Полипептидный маркер для диагноза артериосклероза | |
US20140027283A1 (en) | Method and marker for the diagnosis of a bile duct stricture and of a cholangiocellular carcinoma in bile | |
KR20080074190A (ko) | 혈관성 질환의 진단 및 평가를 위한 폴리펩티드 마커 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090615 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110621 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110620 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110915 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110926 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120828 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121016 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121204 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121207 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151214 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |